RHAPSIDO^® (remibrutinib) demonstrated fast, complete resolution of hives based on TFS at week 12¹

Primary end point: In RemIND, 29.3% of patients on RHAPSIDO (n=17) achieved complete response of hives based on TFS vs. 14.0% of patients on placebo (n=8) at week 12 (one-sided P value=.0229)^1,2,*

*Multiple imputation techniques were implemented for missing data.^1 
†One-sided P value.
TFS range 0-4.¹

Reduction in TFS^1,2

Secondary end points: In RemIND, RHAPSIDO significantly reduced hives based on TFS vs placebo at week 2 (LS mean CFB –1.57 vs. –0.44 with placebo; one-sided P value<.0001) and at week 12 (LS mean CFB –1.56 vs –0.88 with placebo; one-sided P value=.0112)^2,*

*Multiple imputation techniques were implemented for missing data.²

Significant itch reduction^1,2

Secondary end point: In RemIND, RHAPSIDO significantly reduced itch NRS from baseline vs placebo at week 2 (LS mean CFB: –3.98 vs –1.78 placebo; one-sided P value<.0001) and at week 12 (LS mean CFB: –3.78 vs –2.45 placebo; one-sided P value=.007)^1,2,*,†

*Multiple imputation techniques were implemented for missing data.^2
†Based on itch NRS results (range 0-10) for RHAPSIDO at week 2 and week 12 vs placebo following provocation test.^2,3

Reduction in patients’ most bothersome symptom score²

Secondary end point: In RemIND, RHAPSIDO significantly reduced weekly MBS score vs placebo at week 12 (LS mean CFB: –1.96 vs –0.33 placebo; one-sided P value<.0001)^2,*,†

*Multiple imputation techniques were implemented for missing data.^2
†Based on patient diaries. The MBS score range is 0-10.^2,3